Summary
A new slow-release formulation of buserelin given as a 3-month depot injection was evaluated in four patients with advanced prostatic cancer. Treatment was maintained for a mean period of 15 months. Steady-state urinary buserelin concentrations were reached by the beginning of the 3rd week of treatment and maintained until the end of the 3rd month. Serum testosterone remained suppressed in the castrate range for the duration of the study. This preparation offers an advantage for the patient and clinician over existing methods of gonadotrophin-releasing hormone (GnRH) analogue administration and will enter further clinical trial.
This is a preview of subscription content, log in via an institution to check access.
References
Fraser HM, Sandow J, Seidel H, Von Rechenberg W (1987) An implant of a gonadotrophin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3, 5 months. Acta Endocrinol 155: 521
Sandow J, Clayton RN (1981) The disposition metabolism, kinetics and receptor binding properties of LHRH and its analogues. In: Hormone biochemistry and pharmacology, vol 2. Eden, London, 62
Waxman JH, Sandow J, Man A, Hendry WF, Besser GM, Oliver RT, Magill PJ (1986) The first clinical use of depot buserelin for advanced prostatic carcinoma. Cancer Chemother Pharmacol 18: 174
Williams G, Kerle D, Griffin S, Dunlop H, Bloom SR (1984) Biodegradable polymer luteinizing hormone releasing hormone agonist for prostatic cancer: use of a new peptide delivery system. Br Med J 289: 1586
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Waxman, J., Sandow, J., Thomas, H. et al. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer. Cancer Chemother. Pharmacol. 25, 219–220 (1989). https://doi.org/10.1007/BF00689587
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00689587